In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.

BioCryst (NASDAQ:BCRX) released its preliminary 2024 revenue results, along with guidance for 2025.The company said it expects to report 2024 net revenue of $450M, up 36% from the prior year, with ...

64.4% of Immatics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.3% of Immatics shares are held by ...

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding ...

Short interest in BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) decreased during the last reporting period, falling from 17.29M to 15.72M. This put 7.65% of the company's publicly available shares short.

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 7 and set a price target of $10.00. The company’s shares closed last Wednesday at $8.05.